Disclosed herein are antibodies, compositions, and methods of treating allergic responses. In some embodiments, the compositions are combination treatments of more than one antibody. In some embodiments, the antibodies bind to Ara h 2 and/or Ara h 6 and are useful for treating peanut allergies.
A method of inhibiting anaphylaxis includes administering to a subject a composition comprising a first antibody, or fragment thereof, that binds to an allergen and a second antibody, or fragment thereof, that binds to the allergen, wherein the first antibody and the second antibody are from selected, epitope bins for an allergen that show the highest relative efficacy.
Disclosed herein are antibodies, compositions, and methods of treating allergic responses. In some embodiments, the compositions are combination treatments of more than one antibody. In some embodiments, the antibodies bind to Ara h 2 and/or Ara h 6 and are useful for treating peanut allergies.
The present invention provides compositions and methods for preventing an anaphylactoid hypersensitivity reaction in a subject by providing to that subject a combination of antigen-binding IgG and an anti-IgE antibody.
The present invention provides compositions and methods for preventing an anaphylactoid hypersensitivity reaction in a subject by providing to that subject a combination of antigen-binding IgG and an anti-IgE antibody.
A method of inhibiting anaphylaxis includes administering to a subject a composition comprising a first antibody, or fragment thereof, that binds to an allergen and a second antibody, or fragment thereof, that binds to the allergen, wherein the first antibody and the second antibody are from selected, epitope bins for an allergen that show the highest relative efficacy.
The invention generally relates to therapeutic methods for treating and suppressing allergic responses. The invention provides therapeutic compositions and methods for treating and suppressing allergic responses using antibodies, antibody fragments thereof, or other products of the immune system coupled with a steric inhibitor to bind to an epitope on an allergen. Because of the steric inhibitor, the composition prevents one or more IgE antibodies from binding to the allergen. By blocking one or more IgE antibodies from binding to the allergen, the composition prevents IgE-mediated cross-linking and degranulation of mast cells and basophils, thus inhibiting anaphylaxis.
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
A61K 47/51 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
C07K 16/16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from plants
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
8.
COMPOSITIONS AND METHODS FOR TREATING AND SUPPRESSING ALLERGIC RESPONSES
The invention generally relates to therapeutic methods for treating and suppressing allergic responses. The invention provides therapeutic compositions and methods for treating and suppressing allergic responses using antibodies, antibody fragments thereof, or other products of the immune system coupled with a steric inhibitor to bind to an epitope on an allergen. Because of the steric inhibitor, the composition prevents one or more IgE antibodies from binding to the allergen. By blocking one or more IgE antibodies from binding to the allergen, the composition prevents IgE-mediated cross-linking and degranulation of mast cells and basophils, thus inhibiting anaphylaxis.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The invention provides methods of testing food for antigens that are more stable to food processing than more clinically problematic allergens from the same food. When clinically-significant allergens are disproportionately broken down by common preparation methods, the presence of certain food ingredients may be “masked” to some tests yet may still be allergenic. To prevent false negative results due to food preparation, the invention provides tests that test for specific food antigens that are selected on the basis of their stability under processing. Antigens are selected for inclusion in the test not because they are the most clinically relevant allergens, but rather because they are robust to processing (e.g., and do not denature during cooking). Tests of the invention may also test for the most clinically relevant allergens, but importantly, by testing for stable protein products/antigens, the tests report the presence of food residues even after commercial processing.
The invention provides methods of testing food for antigens that are more stable to food processing than more clinically problematic allergens from the same food. When clinically- significant allergens are disproportionately broken down by common preparation methods, the presence of certain food ingredients may be "masked" to some tests yet may still be allergenic. To prevent false negative results due to food preparation, the invention provides tests that test for specific food antigens that are selected on the basis of their stability under processing. Antigens are selected for inclusion in the test not because they are the most clinically relevant allergens, but rather because they are robust to processing (e.g., and do not denature during cooking). Tests of the invention may also test for the most clinically relevant allergens, but importantly, by testing for stable protein products/ antigens, the tests report the presence of food residues even after commercial processing.
The invention provides methods and compositions for treating allergies that use antibodies or other products of the immune system from whom have already experienced and responded to an allergen. In particular, people who have suffered from an allergic reaction to an allergen but subsequently become desensitized to the allergen produce immune products that may be isolated or reproduced for use in a therapeutic composition.
The present invention provides systems and methods for predicting an allergic response in a subject by measuring the amounts of RNA species from B cells that encode at least a part of the Immunoglobulin E (IgE) constant region (Cε), such as nonproductive epsilon germline transcripts (εGLTs).
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
The present invention provides systems and methods for predicting an allergic response in a subject by measuring the amounts of RNA species from B cells that encode at least a part of the Immunoglobulin E (IgE) constant region (Ce), such as nonproductive epsilon germline transcripts (eGLTs).
The invention relates to cross-reactive antibodies or antigen-binding portions thereof with specificity for at least one non-tumor antigen and a tumor antigen.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
15.
COMPOSITIONS AND METHODS FOR TREATING AND SUPPRESSING ALLERGIC RESPONSES
patents
